Molecular Biology Program
The John Maciejowski Lab
The nuclear envelope is a regulated membrane barrier that separates the nucleus from the cytosol in eukaryotes. Although the NE is often depicted as a static barrier, new research has identified conditions where nuclear envelope rupturing causes a loss of compartmentalization. Nuclear envelope ruptures are rapidly repaired in the nucleus, but persist at aberrant, nuclear compartments, such as micronuclei and DNA bridges, that form around mis-segregated chromosomes. Compromised nuclear compartmentalization can result in DNA damage, inflammation, and clustered mutagenesis. The Maciejowski lab seeks to understand how the nuclear envelope safeguards the genome and prevents immune recognition of chromosomal DNA. We approach these problems using a combination of cell biology, biochemistry, and genomics. More information about our research can be found at http://maciejowskilab.com/.
Mohr L, Toufektchan E, von Morgen P, Chu K, Kapoor A, Maciejowski J. ER-directed TREX1 limits cGAS activation at micronuclei. Mol Cell. 2021 Jan 12:S1097-2765(20)30958-8. doi: 10.1016/j.molcel.2020.12.037. Epub ahead of print.
Maciejowski J, Chatzipli A, Dananberg A, Chu K, Toufektchan E, Klimczak LJ, Gordenin DA, Campbell PJ, de Lange T. APOBEC3-dependent kataegis and TREX1-driven chromothripsis during telomere crisis. Nat Genet. 2020 Sep;52(9):884-890. doi: 10.1038/s41588-020-0667-5. Epub 2020 Jul 27. PMCID: PMC7484228.
John Maciejowski, PhD
- Molecular biologist John Maciejowski studies the causes of complex chromosome rearrangements and the patterns of hypermutation that shape cancer genomes.
- PhD, Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center
- [email protected]
- Email Address
- NIH Pathway to Independence Award (2016)
- Tri-Institutional Breakout Prize for Junior Investigators (2016)
- Regeneron Prize for Creative Innovation (2016)
- Pew Biomedical Scholar
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
John Maciejowski discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.